Market Overview:
The global chronic kidney disease (CKD) market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of CKD, rising geriatric population, and technological advancements in the field of renal replacement therapies. Based on type, the global CKD market is segmented into ACE inhibitors, calcium channel blockers, beta blockers, and others. The ACE inhibitors segment accounted for the largest share of the global CKD market in 2017 and is projected to grow at a CAGR of 6% during the forecast period. This growth can be attributed to factors such as increasing incidence of hypertension and diabetes mellitus – major risk factors for developing CKD – across regions worldwide. Based on application, hospitals accounted for the largest share of the global CKD market in 2017.
 Industry Outlook.svg)
Product Definition:
Chronic Kidney Disease (CKD) is a long-term, slowly progressive disease that damages the kidneys and reduces their ability to perform their essential functions. CKD is diagnosed through blood and urine tests that show abnormalities in kidney function. Importantly, CKD often has no symptoms until it has progressed to a more advanced stage. Left untreated, CKD can lead to kidney failure and death. Treatment for CKD focuses on slowing the progression of the disease and managing associated conditions.
ACE Inhibitors:
The global ACE inhibitors market size was valued at USD 4.6 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period due to its use as antihypertensive medication, which prevents heart attacks and strokes by decreasing blood pressure. The American Heart Association (AHA) recommends that people with hypertension should be treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).
Calcium Channel Blockers:
Calcium channel blockers are a class of drugs that act to reduce the ability of the heart to beat quickly and thus lower blood pressure. Calcium channel blockers have been used in the treatment of hypertension, but with little success. With more than 20 different drugs currently available in this category, there is a wide range of drug options for treating high blood pressure.
Application Insights:
The specialty clinics segment dominated the global market in 2017. This is attributed to factors such as increasing prevalence of target diseases, growing awareness about available treatment options, and availability of advanced therapies in this region. For instance, according to data published by the National Chronic Kidney Disease Fact Sheet 2014-2015 by CDC; around 30 million Americans aged 65 years or above have some form of CKD which accounts for around 17% of total U.S. population affected by chronic kidney disease (CKD). In addition, it was estimated that over 1 out of every 2 African American males aged 45 years and above has some form of CKD which is a major factor driving demand for kidney care services across the country.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to high awareness levels about CKD, favorable reimbursement scenario, and availability of effective treatment methods. In addition, presence of key players such as Johnson & Johnson Services LLC; Merck & Co., Inc.; and Pfizer Inc. is also one of the major factors responsible for regional growth.
Asia Pacific is anticipated to be the fastest-growing region over the forecast period owing to rising healthcare expenditure by governments and private sectors in order to improve patient care facilities across emerging countries such as China and India which are leading contributors towards this market’s growth rate. Moreover, increasing geriatric population coupled with lifestyle changes will drive demand for chronic kidney disease treatments in Asia Pacific region over next eight years as per a study published in Journal Of Renal Nutrition And Nephrology in 2016 (Ref: page 7).
Growth Factors:
- Increasing incidence of CKD due to rising prevalence of diabetes and hypertension
- Growing awareness about CKD and its early diagnosis
- Rising demand for renal replacement therapies (RRTs)
- Technological advancements in RRTs
- Increasing number of clinical trials for new drugs and therapies for CKD
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Kidney Disease (CKD) Market Research Report
By Type
ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Others
By Application
Hospitals, Specialty Clinics
By Companies
AbbVie, Allergan, Amgen, AstraZeneca, Roche, FibroGen, GlaxoSmithKline, Johnson & Johnson, Keryx, Kissei, Pfizer, Sanofi, Teva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Kidney Disease (CKD) Market Report Segments:
The global Chronic Kidney Disease (CKD) market is segmented on the basis of:
Types
ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Allergan
- Amgen
- AstraZeneca
- Roche
- FibroGen
- GlaxoSmithKline
- Johnson & Johnson
- Keryx
- Kissei
- Pfizer
- Sanofi
- Teva
 Market Overview.svg)
Highlights of The Chronic Kidney Disease (CKD) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACE Inhibitors
- Calcium Channel Blockers
- Beta Blockers
- Others
- By Application:
- Hospitals
- Specialty Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Kidney Disease (CKD) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic kidney disease (CKD) is a condition in which the kidneys do not work properly over time. The kidneys are responsible for filtering blood and removing waste products from the body. CKD can be caused by many factors, including obesity, diabetes, and high blood pressure.
Some of the major companies in the chronic kidney disease (ckd) market are AbbVie, Allergan, Amgen, AstraZeneca, Roche, FibroGen, GlaxoSmithKline, Johnson & Johnson, Keryx, Kissei, Pfizer, Sanofi, Teva.
The chronic kidney disease (ckd) market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Kidney Disease (CKD) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Kidney Disease (CKD) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Kidney Disease (CKD) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Kidney Disease (CKD) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Kidney Disease (CKD) Market Size & Forecast, 2018-2028
4.5.1 Chronic Kidney Disease (CKD) Market Size and Y-o-Y Growth
4.5.2 Chronic Kidney Disease (CKD) Market Absolute $ Opportunity
Chapter 5 Global Chronic Kidney Disease (CKD) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chronic Kidney Disease (CKD) Market Size Forecast by Type
5.2.1 ACE Inhibitors
5.2.2 Calcium Channel Blockers
5.2.3 Beta Blockers
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chronic Kidney Disease (CKD) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chronic Kidney Disease (CKD) Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Kidney Disease (CKD) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Kidney Disease (CKD) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chronic Kidney Disease (CKD) Analysis and Forecast
9.1 Introduction
9.2 North America Chronic Kidney Disease (CKD) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chronic Kidney Disease (CKD) Market Size Forecast by Type
9.6.1 ACE Inhibitors
9.6.2 Calcium Channel Blockers
9.6.3 Beta Blockers
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chronic Kidney Disease (CKD) Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialty Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chronic Kidney Disease (CKD) Analysis and Forecast
10.1 Introduction
10.2 Europe Chronic Kidney Disease (CKD) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chronic Kidney Disease (CKD) Market Size Forecast by Type
10.6.1 ACE Inhibitors
10.6.2 Calcium Channel Blockers
10.6.3 Beta Blockers
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chronic Kidney Disease (CKD) Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialty Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chronic Kidney Disease (CKD) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chronic Kidney Disease (CKD) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chronic Kidney Disease (CKD) Market Size Forecast by Type
11.6.1 ACE Inhibitors
11.6.2 Calcium Channel Blockers
11.6.3 Beta Blockers
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chronic Kidney Disease (CKD) Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialty Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chronic Kidney Disease (CKD) Analysis and Forecast
12.1 Introduction
12.2 Latin America Chronic Kidney Disease (CKD) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chronic Kidney Disease (CKD) Market Size Forecast by Type
12.6.1 ACE Inhibitors
12.6.2 Calcium Channel Blockers
12.6.3 Beta Blockers
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chronic Kidney Disease (CKD) Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialty Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chronic Kidney Disease (CKD) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chronic Kidney Disease (CKD) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chronic Kidney Disease (CKD) Market Size Forecast by Type
13.6.1 ACE Inhibitors
13.6.2 Calcium Channel Blockers
13.6.3 Beta Blockers
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chronic Kidney Disease (CKD) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialty Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Kidney Disease (CKD) Market: Competitive Dashboard
14.2 Global Chronic Kidney Disease (CKD) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Allergan
14.3.3 Amgen
14.3.4 AstraZeneca
14.3.5 Roche
14.3.6 FibroGen
14.3.7 GlaxoSmithKline
14.3.8 Johnson & Johnson
14.3.9 Keryx
14.3.10 Kissei
14.3.11 Pfizer
14.3.12 Sanofi
14.3.13 Teva
